SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (3474)12/30/1997 4:18:00 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 6136
 
Sustiva has nothing to do with Viracept sales unless Merck can prove that Crix/Sustiva combination is better than any other triple or higher combination. Which they can because Sustiva has also resistance problems as any other RT dug. Your source of info is as well uninformed as you are.
Also, Sustiva has its own competitiors.

mz



To: David S. who wrote (3474)12/30/1997 8:09:00 PM
From: JOHN W.  Read Replies (1) | Respond to of 6136
 
No problem david. Could you expand on how Sustiva will affect any PI sales. Also, who were these people you talked to? Is there any technical rally we will see on Friday, the first trading day of 98?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News